First Western Capital Management Co decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 21.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,068 shares of the medical research company’s stock after selling 1,142 shares during the period. First Western Capital Management Co’s holdings in Amgen were worth $667,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Thomas J. Herzfeld Advisors Inc. acquired a new position in Amgen during the fourth quarter valued at $102,000. Focused Wealth Management Inc raised its position in Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock valued at $127,000 after buying an additional 620 shares in the last quarter. Northwest Quadrant Wealth Management LLC acquired a new position in Amgen during the fourth quarter valued at $157,000. Cable Hill Partners LLC raised its position in Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock valued at $161,000 after buying an additional 26 shares in the last quarter. Finally, Cribstone Capital Management LLC raised its position in Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock valued at $182,000 after buying an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 78.86% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (AMGN) opened at 162.42 on Friday. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The firm has a market cap of $119.44 billion, a P/E ratio of 15.43 and a beta of 1.37. The firm’s 50-day moving average price is $160.16 and its 200-day moving average price is $160.84.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.00 by $0.15. The firm had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.60 billion. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter last year, the business posted $2.90 EPS. On average, equities research analysts expect that Amgen Inc. will post $12.43 EPS for the current fiscal year.

WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/06/18/amgen-inc-amgn-stake-reduced-by-first-western-capital-management-co.html.

AMGN has been the topic of several recent analyst reports. Mizuho set a $195.00 target price on Amgen and gave the stock a “buy” rating in a report on Thursday, March 16th. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the company a “buy” rating in a research note on Monday, March 6th. Cowen and Company reissued a “buy” rating and issued a $209.00 price target on shares of Amgen in a research note on Friday, March 17th. Vetr downgraded Amgen from a “strong-buy” rating to a “buy” rating and set a $178.82 price target on the stock. in a research note on Monday, April 3rd. Finally, BMO Capital Markets reissued a “buy” rating and issued a $198.00 price target (down previously from $200.00) on shares of Amgen in a research note on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $185.49.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.